solute carrier family 39 member 14Genealiases: HCIN · HMNDYT2 · LZT-Hs4 · NET34 · ZIP14 · cig19
Q-omics provides the consensus-scored SLC39A14 profile across patient tissues and cancer cell-line models. SLC39A14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC39A14 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SLC39A14 protein abundance shows 20,239 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where SLC39A14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC39A14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC39A14 survival associations across molecular data types. SLC39A14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC39A14 RNA expression–survival associations across cancer types. High SLC39A14 expression shows unfavorable associations in MESO, KIRP, BLCA, KICH and CESC, but favorable associations in READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC39A14 RNA expression.
This table summarizes SLC39A14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC39A14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC39A14 shows lower tumor expression in THCA and LIHC and higher tumor expression in HNSC, KIRC, LUAD and STAD. The HNSC box plot shows higher SLC39A14 RNA expression in tumor versus normal tissue (log2 FC = +2.300, t-test p < 0.001).
This table shows molecular features associated with SLC39A14 in patient tissues and cancer cell lines. In patient samples, SLC39A14 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC39A14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
